

BIOCON GROUP

FACT SHEET

September - 2013

H1 FY 2014 vs. H1 FY 2013

Q2 FY 2014 vs. Q2 FY 2013

BIOCON LIMITED (CONSOLIDATED) UNAUDITED		
BALANCE SHEET		(Rs. Crores)
	September 30, 2013	March 31, 2013
EQUITY AND LIABILITIES		
Shareholder's Funds		
(a) Share capital	100	100
(b) Reserves and surplus	2,830	2,595
	2,930	2,695
Minority interest	71	65
Non-current liabilities		
(a) Long-term borrowings	335	164
(b) Deferred tax liability (net)	36	41
(c) Other long-term liabilities	488	424
(d) Long-term provisions	6	4
	865	633
Current liabilities		
(a) Short-term borrowings	69	85
(b) Trade payables	394	345
(c) Other current liabilities	338	347
(d) Short-term provisions	104	246
	905	1,023
TOTAL	4,771	4,416
ASSETS		
Non-current assets		
(a) Fixed assets	2,047	1,811
(b) Good will	12	12
(c) Non-current investments	65	64
(d) Long term loans and advances	303	248
(e) Other non-current assets	52	41
	2,479	2,176
Current assets		
(a) Current Investments	476	522
(b) Inventories	422	398
(c) Trade receivables	583	510
(d) Cash and cash equivalents	658	673
(e) Short term loans and advances	64	81
(f) Other current assets	89	56
	2,292	2,240
TOTAL	4,771	4,416

BIOCON LIMITED (CONSOLIDATED) UNAUDITED			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	H1 FY 14	H1 FY 13	Variance
INCOME			
Biopharmaceuticals *	886	734	21%
Branded formulations - India	200	178	12%
Total Biopharmaceuticals	1,086	912	19%
Contract research	343	252	36%
Total Sales	1,429	1,164	23%
Other income	39	71	-45%
Total Revenue	1,468	1,235	19%
EXPENDITURE			
Material & Power costs	678	570	19%
Staff costs	210	172	22%
Research & Development **	82	79	4%
Other expenses	135	109	24%
Manufacturing, staff & other expenses	1,105	930	19%
EBITDA	363	305	19%
Interest & Finance charges	1.00	4	
PBDT	362	301	20%
Depreciation & Amortisation	98	88	11%
PBT BEFORE EXCEPTIONAL ITEM	264	213	24%
Exceptional item, Net		-	
PBT	264	213	24%
Taxes	62	43	44%
NET PROFIT BEFORE MINORITY INTEREST	202	170	19%
Minority interest	6	1	
NET PROFIT FOR THE PERIOD	196	169	16%
EPS Rs.	9.8	8.5	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharmaceuticals Income includes:			
Licensing Income	11	14	
** Gross Research & Development expenses	91	100	

BIOCON LIMITED (CONSOLIDATED) UNAUDITED			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q2 FY 14	Q2 FY 13	Variance
INCOME			
Biopharmaceuticals *	447	372	20%
Branded formulations - India	99	91	9%
Total Biopharmaceuticals	546	463	18%
Contract research	188	129	46%
Total Sales	734	592	24%
Other income	19	50	-62%
Total Revenue	753	642	17%
EXPENDITURE			
Material & Power costs	335	291	15%
Staff costs	103	88	17%
Research & Development **	39	43	-9%
Other expenses	88	54	63%
Manufacturing, staff & other expenses	565	476	19%
EBITDA	188	166	13%
Interest & Finance charges	1	1	
PBDT	187	165	13%
Depreciation & Amortisation	49	45	9%
PBT BEFORE EXCEPTIONAL ITEM	138	120	15%
Exceptional item, Net		-	
PBT	138	120	15%
Taxes	33	30	10%
NET PROFIT BEFORE MINORITY INTEREST	105	90	16%
Minority interest	3	-	
NET PROFIT FOR THE PERIOD	102	90	13%
EPS Rs.	5.1	4.5	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
* Biopharmaceuticals Income includes:			
Licensing Income	3	-	
** Gross Research & Development expenses	45	51	